Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 4/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | CTSD | P07339 | 6/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15865810 | 0.86 | GRM5 (0.38) | GRM2KCNH2ALDH1A1RAB9ANPC1 | |
| SCHEMBL6922074 | 0.81 | CACNA2D1 (0.45) | CACNA2D1ALDH1A1RAB9ANPC1LMNA | |
| SCHEMBL6921994 | 0.81 | METAP2 (0.40) | CACNA2D1RAB9ANPC1METAP2CTSD | |
| SCHEMBL6920768 | 0.79 | GRM5 (0.42) | — | |
| SCHEMBL6920765 | 0.78 | RAB9A (0.43) | GRM2ALDH1A1RAB9ANPC1LMNA | |
| SCHEMBL12039994 | 0.76 | GRM5 (0.38) | ALDH1A1RAB9ANPC1LMNA | |
| SCHEMBL6921956 | 0.75 | RAB9A (0.45) | ALDH1A1RAB9ANPC1LMNACYP3A4 | |
| SCHEMBL12039992 | 0.73 | GRM5 (0.38) | ALDH1A1 | |
| SCHEMBL6923306 | 0.73 | RAB9A (0.43) | GRM2ALDH1A1RAB9ANPC1LMNA | |
| SCHEMBL12059022 | 0.73 | GRM2 (0.39) | GRM2ALDH1A1CTSDCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011075699-A2 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2011-06-23 | — | — | WO | disclosed |